efpeglenatide (HM11260C) / Hanmi, Sanofi  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
efpeglenatide (HM11260C) / Hanmi
AMPLITUDE-M, NCT03353350 / 2016-001857-42: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Completed
3
406
Europe, US, RoW
efpeglenatide (SAR439977), placebo
Hanmi Pharmaceutical Company Limited, Sanofi
Type 2 Diabetes Mellitus
01/20
09/20
AMPLITUDE-D, NCT03684642 / 2017-002956-10: Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Terminated
3
908
Europe, US, RoW
Efpeglenatide, SAR439977, Dulaglutide, Trulicity™, Background therapy Metformin
Sanofi, Hanmi Pharmaceutical Company Limited
Type 2 Diabetes Mellitus
10/20
11/20
AMPLITUDE-L, NCT03713684: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Terminated
3
370
US, RoW
Efpeglenatide SAR439977, Placebo, Background therapy
Sanofi, Hanmi Pharmaceutical Company Limited
Type 2 Diabetes Mellitus
11/20
01/21
AMPLITUDE-S, NCT03770728: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

Terminated
3
312
US, RoW
Efpeglenatide SAR439977, Placebo, Background therapy: Metformin alone or in combination with SU
Sanofi, Hanmi Pharmaceutical Company Limited
Type 2 Diabetes Mellitus
11/20
12/20
AMPLITUDE-O, NCT03496298 / 2017-002954-35: Effect of Efpeglenatide on Cardiovascular Outcomes

Terminated
3
4076
Europe, Canada, US, RoW
Efpeglenatide (SAR439977), Placebo
Sanofi, Hanmi Pharmaceutical Company Limited
Type 2 Diabetes Mellitus
12/20
12/20
NCT06174779: A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

Not yet recruiting
3
420
NA
HM11260C, Placebo
Hanmi Pharmaceutical Company Limited
Obesity
12/25
07/26

Download Options